iEcure Receives Three FDA Designations for its In Vivo Gene Insertion Program 

iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506, which aims to help newborns with a rare liver disorder called OTC deficiency. These designations support the development of treatments for rare conditions and could speed up the approval process for ECUR-506. The company plans to treat its first patient in a clinical trial later this year. Read more here

Skip to content